New data presentation from AIPAC-003 Phase II for SABCS
Filed with ASX · · 2 pages · English
• Immunotherapy-chemotherapy combination of eftilagimod alfa (efti) and paclitaxel led to strong objective response rates and immune activation in heavily pretreated metastatic breast cancer patients • AIPAC-003 has resulted in successful completion of FDA’s Project Optimus requirements and selection of 30 mg as efti’s optimal biological dose SYDNEY, AUSTRALIA – December 2, 2025 – Immutep Limited
Earlier from Immutep
- Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025
- EFTISARC-NEO Phase II results presented at CTOS 2025
- Immutep Receives A$4.6 million R&D Tax Incentive from French Government
- Immutep Receives A$4.6 million French R&D Tax Incentive
- Immutep Quarterly Activities Report Q1 FY26
Later from Immutep
- Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium
- Immutep enters into Strategic Collaboration with Dr. Reddy's
- Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa
- TACTI-004 phase III trial enrolment continues at robust pace
- Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep